Kura Oncology (NASDAQ:KURA) posted its quarterly earnings data on Tuesday. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08, Morningstar.com reports.
Shares of Kura Oncology stock traded up $1.49 on Wednesday, reaching $16.96. 417,918 shares of the stock were exchanged, compared to its average volume of 197,856. Kura Oncology has a 1-year low of $10.20 and a 1-year high of $22.00. The company has a quick ratio of 13.31, a current ratio of 13.31 and a debt-to-equity ratio of 0.05. The firm has a market cap of $647.62 million, a price-to-earnings ratio of -9.86 and a beta of 2.79.
A number of research analysts have commented on the stock. HC Wainwright set a $31.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a research note on Wednesday. BidaskClub upgraded shares of Kura Oncology from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 11th. Oppenheimer restated a “buy” rating on shares of Kura Oncology in a research note on Tuesday, March 19th. Zacks Investment Research lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, January 8th. Finally, ValuEngine upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, March 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $28.20.
Institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in shares of Kura Oncology by 46.9% during the third quarter. Wells Fargo & Company MN now owns 42,222 shares of the company’s stock worth $739,000 after acquiring an additional 13,489 shares during the period. Fosun International Ltd acquired a new position in shares of Kura Oncology during the fourth quarter worth about $2,643,000. Rhumbline Advisers increased its stake in shares of Kura Oncology by 59.1% during the fourth quarter. Rhumbline Advisers now owns 37,118 shares of the company’s stock worth $521,000 after acquiring an additional 13,781 shares during the period. MetLife Investment Advisors LLC increased its stake in shares of Kura Oncology by 111.6% during the third quarter. MetLife Investment Advisors LLC now owns 21,375 shares of the company’s stock worth $374,000 after acquiring an additional 11,273 shares during the period. Finally, Prosight Management LP increased its stake in shares of Kura Oncology by 24.8% during the fourth quarter. Prosight Management LP now owns 316,581 shares of the company’s stock worth $4,445,000 after acquiring an additional 62,950 shares during the period. Institutional investors and hedge funds own 84.99% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Equities Focus and is owned by of Equities Focus. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.equitiesfocus.com/2019/05/09/kura-oncology-kura-announces-earnings-results.html.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Further Reading: What is the LIBOR?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.